inclusion criteria: 1. male or female 18 to 50 years of age, inclusive, at the time of signing the informed consent. 2. subjects must have mild to moderate covid-19 with symptom onset within 5 days prior to study drug administration (see appendix 13.1 for food and drug administration \[fda\] severity guidance). subjects whose symptoms began \>5 days (i.e. ˃120 hours) prior to dosing or whose time of symptom onset cannot be accurately assessed are not eligible. 3. subjects must have at least 2 of the following covid-19 symptoms: fever, cough, sore throat, rhinorrhea, malaise, headache, muscle pain, nausea, vomiting, diarrhea, and loss of taste or smell, or other symptoms that the principal investigator judges to be referrable to covid-19. 4. subjects must be able to maintain oxygen saturation (spo2) ≥ 94% on room air (no supplemental oxygen). 5. body mass index ≥ 18.0 and ≤ 30.0 kg/m2. 6. body weight ≥ 40 kg at screening. 7. sexually active subjects of reproductive potential must agree to use highly effective contraception from signing of the informed consent through 90 days after infusion of the study drug (see section 7.4). 8. males must agree not to donate sperm from dosing until 90 days after administration of the study drug. 9. subjects must have been in generally good health, as judged by the principal investigator, prior to onset of current covid-19 illness, with no clinically significant medical history. 10. subjects must be without clinically significant abnormalities as assessed by review of medical and surgical history, physical examination, vital signs measurement, ecg, and laboratory evaluations conducted at screening.

inclusion criteria: 1. male or female 18 to 50 years of age, inclusive, at the time of signing the informed consent. 2. subjects must have mild to moderate covid-19 with symptom onset within 5 days prior to study drug administration (see appendix 13.1 for food and drug administration \[fda\] severity guidance). subjects whose symptoms began \>5 days (i.e. ˃120 hours) prior to dosing or whose time of symptom onset cannot be accurately assessed are not eligible. 3. subjects must have at least 2 of the following covid-19 symptoms: fever, cough, sore throat, rhinorrhea, malaise, headache, muscle pain, nausea, vomiting, diarrhea, and loss of taste or smell, or other symptoms that the principal investigator judges to be referrable to covid-19. 4. subjects must be able to maintain oxygen saturation (spo2) ≥ 94% on room air (no supplemental oxygen). 5. body mass index ≥ 18.0 and ≤ 30.0 kg/m2. 6. body weight ≥ 40 kg at screening. 7. sexually active subjects of reproductive potential must agree to use highly effective contraception from signing of the informed consent through 90 days after infusion of the study drug (see section 7.4). 8. males must agree not to donate sperm from dosing until 90 days after administration of the study drug. 9. subjects must have been in generally good health, as judged by the principal investigator, prior to onset of current covid-19 illness, with no clinically significant medical history. 10. subjects must be without clinically significant abnormalities as assessed by review of medical and surgical history, physical examination, vital signs measurement, ecg, and laboratory evaluations conducted at screening.

inclusion criteria: male or female 18 to 50 years of age, inclusive, at the time of signing the informed consent. subjects must have mild to moderate covid-19 with symptom onset within 5 days prior to study drug administration (see appendix 13.1 for food and drug administration [fda] severity guidance). subjects whose symptoms began >5 days (i.e. ˃120 hours) prior to dosing or whose time of symptom onset cannot be accurately assessed are not eligible. subjects must have at least 2 of the following covid-19 symptoms: fever, cough, sore throat, rhinorrhea, malaise, headache, muscle pain, nausea, vomiting, diarrhea, and loss of taste or smell, or other symptoms that the principal investigator judges to be referrable to covid-19. subjects must be able to maintain oxygen saturation (spo2) ≥ 94% on room air (no supplemental oxygen). body mass index ≥ 18.0 and ≤ 30.0 kg/m2. body weight ≥ 40 kg at screening. sexually active subjects of reproductive potential must agree to use highly effective contraception from signing of the informed consent through 90 days after infusion of the study drug (see section 7.4). males must agree not to donate sperm from dosing until 90 days after administration of the study drug. subjects must have been in generally good health, as judged by the principal investigator, prior to onset of current covid-19 illness, with no clinically significant medical history. subjects must be without clinically significant abnormalities as assessed by review of medical and surgical history, physical examination, vital signs measurement, ecg, and laboratory evaluations conducted at screening.

inclusion criteria: male or female 18 to 50 years of age, inclusive, at the time of signing the informed consent. subjects must have mild to moderate covid-19 with symptom onset within 5 days prior to study drug administration (see appendix 13.1 for food and drug administration [fda] severity guidance). subjects whose symptoms began >5 days (i.e. ˃120 hours) prior to dosing or whose time of symptom onset cannot be accurately assessed are not eligible. subjects must have at least 2 of the following covid-19 symptoms: fever, cough, sore throat, rhinorrhea, malaise, headache, muscle pain, nausea, vomiting, diarrhea, and loss of taste or smell, or other symptoms that the principal investigator judges to be referrable to covid-19. subjects must be able to maintain oxygen saturation (spo2) ≥ 94% on room air (no supplemental oxygen). body mass index ≥ 18.0 and ≤ 30.0 kg/m2. body weight ≥ 40 kg at screening. sexually active subjects of reproductive potential must agree to use highly effective contraception from signing of the informed consent through 90 days after infusion of the study drug (see section 7.4). males must agree not to donate sperm from dosing until 90 days after administration of the study drug. subjects must have been in generally good health, as judged by the principal investigator, prior to onset of current covid-19 illness, with no clinically significant medical history. subjects must be without clinically significant abnormalities as assessed by review of medical and surgical history, physical examination, vital signs measurement, ecg, and laboratory evaluations conducted at screening.